<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mult Scler</journal-id><journal-id journal-id-type="iso-abbrev">Mult Scler</journal-id><journal-id journal-id-type="publisher-id">MSJ</journal-id><journal-id journal-id-type="hwp">spmsj</journal-id><journal-title-group><journal-title>Multiple Sclerosis (Houndmills, Basingstoke, England)</journal-title></journal-title-group><issn pub-type="ppub">1352-4585</issn><issn pub-type="epub">1477-0970</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40099830</article-id><article-id pub-id-type="pmc">PMC12092947</article-id>
<article-id pub-id-type="doi">10.1177/13524585251326841</article-id><article-id pub-id-type="publisher-id">10.1177_13524585251326841</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Papers</subject><subj-group subj-group-type="heading"><subject>Predictive Factors &#x00026; Clinical Monitoring</subject></subj-group></subj-group></article-categories><title-group><article-title>Seizure history and cognitive dysfunction in people with multiple sclerosis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4340-3232</contrib-id><name><surname>Freedman</surname><given-names>David E</given-names></name><xref rid="corresp1-13524585251326841" ref-type="corresp"/><aff id="aff1-13524585251326841">Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada</aff><aff id="aff2-13524585251326841">Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5519-6088</contrib-id><name><surname>Oh</surname><given-names>Jiwon</given-names></name><aff id="aff3-13524585251326841">Division of Neurology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada</aff><aff id="aff4-13524585251326841">Department of Medicine, Division of Neurology, St. Michael&#x02019;s Hospital, Toronto, ON, Canada</aff></contrib><contrib contrib-type="author"><name><surname>Meza</surname><given-names>Cecilia</given-names></name><aff id="aff5-13524585251326841">Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0132-0909</contrib-id><name><surname>Feinstein</surname><given-names>Anthony</given-names></name><aff id="aff6-13524585251326841">Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada</aff><aff id="aff7-13524585251326841">Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada</aff></contrib></contrib-group><author-notes><corresp id="corresp1-13524585251326841">DE Freedman Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada. <email>david.freedman@sunnybrook.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2025</year></pub-date><volume>31</volume><issue>6</issue><fpage>668</fpage><lpage>676</lpage><history><date date-type="received"><day>26</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>21</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s), 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><sec id="section1-13524585251326841"><title>Background:</title><p>Seizures are associated with reduced cognition in the general population and worse outcomes in people with multiple sclerosis (pwMS). Yet, it remains unclear whether seizures are linked to cognitive dysfunction in pwMS.</p></sec><sec id="section2-13524585251326841"><title>Objectives:</title><p>To evaluate the connection between seizure history and poorer cognition in pwMS.</p></sec><sec id="section3-13524585251326841"><title>Methods:</title><p>A consecutive sample of 803 pwMS reported any prior seizures. Covariates included age, sex, Wechsler Test of Adult Reading scores, educational years, Expanded Disability Status Scale (EDSS) scores, disease duration, disease subtype, high-efficacy disease-modifying therapy use, Hospital Anxiety and Depression Scale scores for anxiety and depression and Modified Fatigue Impact Scale scores. Linear regression analyses, controlling for covariates, were undertaken to predict Minimal Assessment of Cognitive Function in MS scores from seizure history.</p></sec><sec id="section4-13524585251326841"><title>Results:</title><p>Mean age was 44.01 years (<italic toggle="yes">SD</italic> = 11.58), 76.84% were female, and median EDSS was 2.0 (interquartile range (IQR) = 1.5&#x02013;3.5). Accounting for covariates, people with seizures (<italic toggle="yes">n</italic> = 43, 5.35%) performed worse than those without (<italic toggle="yes">n</italic> = 760) on Judgement of Line Orientation (&#x003b2; = &#x02212;0.09, <italic toggle="yes">p</italic> &#x0003c; 0.01), California Verbal Learning Test-II learning (&#x003b2; = &#x02212;0.08, <italic toggle="yes">p</italic> &#x0003c; 0.01) and memory (&#x003b2; = &#x02212;0.10, <italic toggle="yes">p</italic> &#x0003c; 0.01), Brief Visuospatial Memory Test-Revised learning (&#x003b2; = &#x02212;0.08, <italic toggle="yes">p</italic> = 0.01) and memory (&#x003b2; = &#x02212;0.07, <italic toggle="yes">p</italic> = 0.05), Symbol Digit Modalities Test (&#x003b2; = &#x02212;0.06, <italic toggle="yes">p</italic> = 0.04), Paced Auditory Serial Addition Test (&#x003b2; = &#x02212;0.10, <italic toggle="yes">p</italic> &#x0003c; 0.01) and Delis-Kaplan Executive Function System (&#x003b2; = &#x02212;0.07, <italic toggle="yes">p</italic> = 0.02).</p></sec><sec id="section5-13524585251326841"><title>Conclusions:</title><p>A seizure history independently predicts reduced cognition in pwMS.</p></sec></abstract><kwd-group><kwd>Multiple sclerosis</kwd><kwd>outcome measurement</kwd><kwd>seizure</kwd><kwd>cognition</kwd><kwd>neuropsychology</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-13524585251326841"><funding-source id="funding1-13524585251326841">
<institution-wrap><institution>Sunnybrook Foundation</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100019746</institution-id></institution-wrap>
</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section6-13524585251326841"><title>Introduction</title><p>Cognitive dysfunction affects 40%&#x02013;90% of people with multiple sclerosis (pwMS),<sup><xref rid="bibr1-13524585251326841" ref-type="bibr">1</xref>,<xref rid="bibr2-13524585251326841" ref-type="bibr">2</xref></sup> and contributes to reduced quality of life and increased unemployment.<sup><xref rid="bibr3-13524585251326841" ref-type="bibr">3</xref>,<xref rid="bibr4-13524585251326841" ref-type="bibr">4</xref></sup> It is thus important to identify those at risk of cognitive dysfunction in pwMS. Studies have suggested that reduced cognition in MS is associated with older age, male sex, low premorbid intelligence, decreased education, increased neurological disability, prolonged disease duration, disease course and depression, especially with comorbid anxiety.<sup><xref rid="bibr1-13524585251326841" ref-type="bibr">1</xref>,<xref rid="bibr5-13524585251326841" ref-type="bibr">5</xref><xref rid="bibr6-13524585251326841" ref-type="bibr"/>&#x02013;<xref rid="bibr7-13524585251326841" ref-type="bibr">7</xref></sup> Cognition is also associated with whole brain atrophy, reduced grey matter volume, thalamic atrophy and an elevated total white matter lesion volume burden.<sup><xref rid="bibr2-13524585251326841" ref-type="bibr">2</xref>,<xref rid="bibr8-13524585251326841" ref-type="bibr">8</xref>,<xref rid="bibr9-13524585251326841" ref-type="bibr">9</xref></sup> Yet, apart from comorbid depression and anxiety,<sup>
<xref rid="bibr7-13524585251326841" ref-type="bibr">7</xref>
</sup> there are few independent modifiable targets to enhance cognition in pwMS.</p><p>Seizures could be one such target. Seizures occur in 1%&#x02013;3% of pwMS, approximately two to three times more commonly than in the general population.<sup><xref rid="bibr10-13524585251326841" ref-type="bibr">10</xref>,<xref rid="bibr11-13524585251326841" ref-type="bibr">11</xref></sup> Potential risk factors for seizures in MS include prolonged disease duration, increased disability, progressive illness, use of sphingosine-1-phosphate receptor modulators, brain atrophy, cortical involvement, temporal lobe lesions and thalamic dysfunction.<sup><xref rid="bibr12-13524585251326841" ref-type="bibr">12</xref><xref rid="bibr13-13524585251326841" ref-type="bibr"/><xref rid="bibr14-13524585251326841" ref-type="bibr"/>&#x02013;<xref rid="bibr15-13524585251326841" ref-type="bibr">15</xref></sup> Seizures are associated with adverse outcomes for pwMS, including elevated disease progression, reduced walking distance, decreased employment and increased mortality.<sup><xref rid="bibr16-13524585251326841" ref-type="bibr">16</xref>,<xref rid="bibr17-13524585251326841" ref-type="bibr">17</xref></sup> However, little is known about whether there is a link between a history of seizures and cognition in pwMS.</p><p>In the general population, a history of seizures is linked to cognitive dysfunction.<sup><xref rid="bibr18-13524585251326841" ref-type="bibr">18</xref>,<xref rid="bibr19-13524585251326841" ref-type="bibr">19</xref></sup> Although this relationship may be partially due to the effects of seizure frequency and severity (or inter-ictal activity) on cognition, other contributors include cognitive reserve, developmental factors, depression, brain pathology and the influence of anti-epileptic drugs.<sup>
<xref rid="bibr19-13524585251326841" ref-type="bibr">19</xref>
</sup> The complex association between seizures and cognition may be further complicated by the impact of MS.</p><p>In pwMS, studies have found elevated subjective cognitive concerns and objectively measured dysfunction in people with seizures and MS compared to those without seizures.<sup><xref rid="bibr14-13524585251326841" ref-type="bibr">14</xref>,<xref rid="bibr16-13524585251326841" ref-type="bibr">16</xref>,<xref rid="bibr20-13524585251326841" ref-type="bibr">20</xref>,<xref rid="bibr21-13524585251326841" ref-type="bibr">21</xref></sup> However, these studies are limited by small sample size,<sup><xref rid="bibr14-13524585251326841" ref-type="bibr">14</xref>,<xref rid="bibr20-13524585251326841" ref-type="bibr">20</xref>,<xref rid="bibr21-13524585251326841" ref-type="bibr">21</xref></sup> lack of objective neuropsychological testing,<sup><xref rid="bibr14-13524585251326841" ref-type="bibr">14</xref>,<xref rid="bibr16-13524585251326841" ref-type="bibr">16</xref></sup> the absence of an MS-validated neuropsychological battery<sup><xref rid="bibr14-13524585251326841" ref-type="bibr">14</xref>,<xref rid="bibr16-13524585251326841" ref-type="bibr">16</xref>,<xref rid="bibr21-13524585251326841" ref-type="bibr">21</xref></sup> or failing to adjust for potential confounding variables (e.g. level of neurological disability, disease duration, etc.).<sup><xref rid="bibr14-13524585251326841" ref-type="bibr">14</xref>,<xref rid="bibr16-13524585251326841" ref-type="bibr">16</xref>,<xref rid="bibr20-13524585251326841" ref-type="bibr">20</xref>,<xref rid="bibr21-13524585251326841" ref-type="bibr">21</xref></sup> No study has evaluated whether a seizure history is independently linked to objectively measured cognitive dysfunction in pwMS. We address this gap in the MS literature with a large, consecutively recruited clinical sample. This study&#x02019;s objective was to evaluate for an independent association between a seizure history and reduced cognition in pwMS.</p></sec><sec sec-type="methods" id="section7-13524585251326841"><title>Methods</title><p>Participants were a consecutive sample of 803 adults with MS (assessed with the McDonald criteria)<sup><xref rid="bibr22-13524585251326841" ref-type="bibr">22</xref>,<xref rid="bibr23-13524585251326841" ref-type="bibr">23</xref></sup> who completed neuropsychological testing as part of routine clinical care at a tertiary neuropsychiatry clinic in Toronto, Canada between 2020 and 2024. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines, with the associated checklist for this study included as <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/13524585251326841" ext-link-type="uri">Supplementary Table 1</ext-link>.<sup>
<xref rid="bibr24-13524585251326841" ref-type="bibr">24</xref>
</sup></p><sec id="section8-13524585251326841"><title>Demographic and disease-related data</title><p>Demographic and disease-related data were documented from chart review and included age, sex, years of education, Expanded Disability Status Scale (EDSS),<sup>
<xref rid="bibr25-13524585251326841" ref-type="bibr">25</xref>
</sup> disease subtype, disease duration and use of disease-modifying therapy (DMT).</p></sec><sec id="section9-13524585251326841"><title>Seizure history and cognitive data</title><p>A seizure history is routinely elicited by self-report as part of obtaining a history before neuropsychological testing. Any previous reported seizure constituted a seizure history (dichotomized by its presence or absence).</p><p>Cognition was assessed using raw scores from the Minimal Assessment of Cognitive Function in MS (MACFIMS), a neuropsychological battery designed and validated for pwMS.<sup><xref rid="bibr26-13524585251326841" ref-type="bibr">26</xref>,<xref rid="bibr27-13524585251326841" ref-type="bibr">27</xref></sup> The MACFIMS includes tests of verbal fluency (Controlled Oral Word Association Test; COWAT), visuospatial function (Judgement of Line Orientation; JOLO), verbal learning and memory (California Verbal Learning Test &#x02013; second edition; CVLT_TL for learning and CVLT_DR for delayed recall), visual learning and memory (Brief Visuospatial Memory Test &#x02013; Revised; BVMT_TL for learning and BVMT_DR for delayed recall), processing speed (Symbol Digit Modalities Test; SDMT), working memory (Paced Auditory Serial Addition Test; two-second (PASAT_2 sec) and three-second (PASAT_3 sec) versions) and executive function (Delis-Kaplan Executive Function System; D-KEFS_CS for correct sorts score and D-KEFS_DS for descriptive score).<sup>
<xref rid="bibr26-13524585251326841" ref-type="bibr">26</xref>
</sup> Premorbid intelligence quotient was estimated by Wechsler Test of Adult Reading (WTAR) scores.<sup>
<xref rid="bibr28-13524585251326841" ref-type="bibr">28</xref>
</sup></p><p>Symptoms of anxiety and depression were recorded by the Hospital Anxiety and Depression Scale,<sup>
<xref rid="bibr29-13524585251326841" ref-type="bibr">29</xref>
</sup> previously validated for use in pwMS.<sup>
<xref rid="bibr30-13524585251326841" ref-type="bibr">30</xref>
</sup> We mean-centred HADS-A and HADS-D sub-scales and multiplied these scores to compute an interaction score (HADS-A &#x000d7; HADS-D), in keeping with prior work.<sup>
<xref rid="bibr7-13524585251326841" ref-type="bibr">7</xref>
</sup> Fatigue was measured with the Modified Fatigue Impact Scale (MFIS),<sup>
<xref rid="bibr31-13524585251326841" ref-type="bibr">31</xref>
</sup> also validated for use in pwMS.<sup>
<xref rid="bibr32-13524585251326841" ref-type="bibr">32</xref>
</sup></p></sec><sec id="section10-13524585251326841"><title>Statistical analysis</title><p>Demographic, disease-related and cognitive data of people with or without a history of seizures were compared using <italic toggle="yes">t</italic>-tests and chi-square tests, where appropriate. Cognitive data comparison effect sizes were reported with the Hedge&#x02019;s <italic toggle="yes">g</italic> statistic.</p><p>A linear regression analyses was used to assess whether a seizure history independently predicted decreased MACFIMS raw scores. Covariates included age, sex, WTAR scores, years of education, EDSS scores, disease duration, disease subtype (relapsing-remitting versus progressive MS), use of a high-efficacy DMT (e.g. ocrelizumab, ofatumumab, natalizumab or alemtuzumab), centred HADS-D and HADS-A scores, a HADS-A &#x000d7; HADS-D interaction and MFIS total score. These covariates were selected based on prior literature that suggested that these variables may influence rates of cognitive dysfunction or seizures in people with MS.<sup><xref rid="bibr1-13524585251326841" ref-type="bibr">1</xref>,<xref rid="bibr5-13524585251326841" ref-type="bibr">5</xref><xref rid="bibr6-13524585251326841" ref-type="bibr"/>&#x02013;<xref rid="bibr7-13524585251326841" ref-type="bibr">7</xref>,<xref rid="bibr12-13524585251326841" ref-type="bibr">12</xref><xref rid="bibr13-13524585251326841" ref-type="bibr"/>&#x02013;<xref rid="bibr14-13524585251326841" ref-type="bibr">14</xref></sup> To preserve the original data and in light of a small amount of missing data, participants with missing data in each analysis were excluded via listwise deletion. The significance threshold was set at <italic toggle="yes">p</italic> &#x0003c; 0.05. As no directly comparable study was available, based on the available sample size (<italic toggle="yes">n</italic> = 803), a desired power of 0.80, <italic toggle="yes">p</italic> &#x0003c; 0.05 and 13 predictor variables, the study was powered to detect standardized beta coefficients of 0.15 or above, equivalent to small effect sizes based on Cohen&#x02019;s guidelines.<sup>
<xref rid="bibr33-13524585251326841" ref-type="bibr">33</xref>
</sup> Power calculations were conducted using R studio (pwr package).<sup>
<xref rid="bibr34-13524585251326841" ref-type="bibr">34</xref>
</sup></p></sec><sec id="section11-13524585251326841"><title>Standard protocol approvals, registrations and patient consents</title><p>This study involving human participants was performed in line with the principles of the Declaration of Helsinki. The study was approved by the Research Ethics Board at Sunnybrook Health Sciences Centre, affiliated to the University of Toronto (Date: 30 December 2021/No. 5263). Data were collected as part of a retrospective chart review and a waiver of consent was obtained as part of the research ethics board approval process.</p></sec><sec sec-type="data-availability" id="section12-13524585251326841"><title>Data availability</title><p>The dataset is available from the corresponding author upon reasonable request.</p></sec></sec><sec sec-type="results" id="section13-13524585251326841"><title>Results</title><sec id="section14-13524585251326841"><title>Demographic and disease-related data</title><p>Of 803 participants, mean age was 44.01 years (<italic toggle="yes">SD</italic> = 11.58), years of education was 15.99 years (<italic toggle="yes">SD</italic> = 2.93), disease duration was 10.16 years (<italic toggle="yes">SD</italic> = 9.07), HADS-A score was 9.91 (SD = 4.32) and HADS-D score (7.14 (SD = 4.07). Median EDSS was 2.00 (interquartile range (IQR) = 1.50&#x02013;3.50). Most participants were female (76.83%), had relapsing-remitting MS (83.69%) and took a DMT (66.06%). There were no significant differences between people with and without a seizure history regarding age, sex distribution, WTAR scores, years of education, EDSS scores, disease duration, disease subtype, use of DMT or scores on the HADS-A, HADS-D or MFIS. <xref rid="table1-13524585251326841" ref-type="table">Table 1</xref> describes demographic and disease-related data according to seizure history.</p><table-wrap position="float" id="table1-13524585251326841"><label>Table 1.</label><caption><p>Demographic and disease-related data stratified by history of seizures.</p></caption><alternatives><graphic xlink:href="10.1177_13524585251326841-table1" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="2" rowspan="1">No history of seizures (<italic toggle="yes">n</italic> = 760)</th><th align="left" colspan="2" rowspan="1">History of seizures (<italic toggle="yes">n</italic> = 43)</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">t</italic>
</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">M</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SD</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">M</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SD</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">43.94</td><td rowspan="1" colspan="1">11.46</td><td rowspan="1" colspan="1">45.28</td><td rowspan="1" colspan="1">13.49</td><td rowspan="1" colspan="1">0.74</td></tr><tr><td rowspan="1" colspan="1">Years of education</td><td rowspan="1" colspan="1">15.98</td><td rowspan="1" colspan="1">2.90</td><td rowspan="1" colspan="1">16.16</td><td rowspan="1" colspan="1">3.44</td><td rowspan="1" colspan="1">0.40</td></tr><tr><td rowspan="1" colspan="1">Wechsler Test of Adult Reading (WTAR)</td><td rowspan="1" colspan="1">37.76</td><td rowspan="1" colspan="1">7.56</td><td rowspan="1" colspan="1">36.92</td><td rowspan="1" colspan="1">9.07</td><td rowspan="1" colspan="1">0.66</td></tr><tr><td rowspan="1" colspan="1">Expanded disability status scale (EDSS)</td><td rowspan="1" colspan="1">2.65</td><td rowspan="1" colspan="1">1.71</td><td rowspan="1" colspan="1">3.00</td><td rowspan="1" colspan="1">2.01</td><td rowspan="1" colspan="1">1.28</td></tr><tr><td rowspan="1" colspan="1">EDSS (Median and Interquartile Range)</td><td rowspan="1" colspan="1">2.0</td><td rowspan="1" colspan="1">1.5&#x02013;3.5</td><td rowspan="1" colspan="1">2.5</td><td rowspan="1" colspan="1">2.0&#x02013;3.5</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Disease duration (years)</td><td rowspan="1" colspan="1">10.07</td><td rowspan="1" colspan="1">8.99</td><td rowspan="1" colspan="1">10.84</td><td rowspan="1" colspan="1">10.48</td><td rowspan="1" colspan="1">0.54</td></tr><tr><td rowspan="1" colspan="1">HADS-A</td><td rowspan="1" colspan="1">9.89</td><td rowspan="1" colspan="1">4.31</td><td rowspan="1" colspan="1">10.31</td><td rowspan="1" colspan="1">4.54</td><td rowspan="1" colspan="1">0.61</td></tr><tr><td rowspan="1" colspan="1">HADS-D</td><td rowspan="1" colspan="1">7.09</td><td rowspan="1" colspan="1">4.02</td><td rowspan="1" colspan="1">7.98</td><td rowspan="1" colspan="1">4.94</td><td rowspan="1" colspan="1">1.37</td></tr><tr><td rowspan="1" colspan="1">Modified Fatigue Impact Scale (MFIS)</td><td rowspan="1" colspan="1">49.85</td><td rowspan="1" colspan="1">16.48</td><td rowspan="1" colspan="1">53.63</td><td rowspan="1" colspan="1">17.33</td><td rowspan="1" colspan="1">1.41</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</td><td rowspan="1" colspan="1">%</td><td rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</td><td rowspan="1" colspan="1">%</td><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup></td></tr><tr><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">581/760</td><td rowspan="1" colspan="1">76.45</td><td rowspan="1" colspan="1">36/43</td><td rowspan="1" colspan="1">83.72</td><td rowspan="1" colspan="1">1.21</td></tr><tr><td rowspan="1" colspan="1">Disease subtype (RRMS vs PMS)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.71</td></tr><tr><td rowspan="1" colspan="1">&#x02003;RRMS</td><td rowspan="1" colspan="1">638/760</td><td rowspan="1" colspan="1">83.95</td><td rowspan="1" colspan="1">34/43</td><td rowspan="1" colspan="1">79.07</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;SPMS</td><td rowspan="1" colspan="1">59/760</td><td rowspan="1" colspan="1">7.76</td><td rowspan="1" colspan="1">5/43</td><td rowspan="1" colspan="1">11.63</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;PPMS</td><td rowspan="1" colspan="1">63/760</td><td rowspan="1" colspan="1">8.29</td><td rowspan="1" colspan="1">4/43</td><td rowspan="1" colspan="1">9.30</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Any disease-modifying therapy</td><td rowspan="1" colspan="1">580/759</td><td rowspan="1" colspan="1">76.42</td><td rowspan="1" colspan="1">30/43</td><td rowspan="1" colspan="1">69.77</td><td rowspan="1" colspan="1">0.99</td></tr><tr><td rowspan="1" colspan="1">&#x02003;High-efficacy therapy (e.g. ocrelizumab, ofatumumab, natalizumab, alemtuzumab)</td><td rowspan="1" colspan="1">272/756</td><td rowspan="1" colspan="1">35.98</td><td rowspan="1" colspan="1">12/43</td><td rowspan="1" colspan="1">27.91</td><td rowspan="1" colspan="1">1.16</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-13524585251326841"><p>HADS-A: Hospital Anxiety and Depression Scale sub-scales for anxiety; HADS-D: Hospital Anxiety and Depression Scale sub-scales for depression; RRMS: relapsing-remitting MS; PMS: progressive MS; SPMS: secondary PMS; PPMS: primary PMS.</p></fn><fn id="table-fn2-13524585251326841"><label>*</label><p><italic toggle="yes">p</italic> &#x0003c; 0.05; **<italic toggle="yes">p</italic> &#x0003c; 0.01.</p></fn></table-wrap-foot></table-wrap><p>As described in <xref rid="table2-13524585251326841" ref-type="table">Table 2</xref>, people with a seizure history performed more poorly than those without a history of seizures on the JOLO (Hedge&#x02019;s <italic toggle="yes">g</italic> = 0.55, <italic toggle="yes">p</italic> &#x0003c; 0.01), CVLT_TL (Hedge&#x02019;s <italic toggle="yes">g</italic> = 0.47, <italic toggle="yes">p</italic> &#x0003c; 0.01), CVLT_DR (Hedge&#x02019;s <italic toggle="yes">g</italic> = 0.49, <italic toggle="yes">p</italic> &#x0003c; 0.01), BVMT_TL (Hedge&#x02019;s <italic toggle="yes">g</italic> = 0.47, <italic toggle="yes">p</italic> &#x0003c; 0.01), BVMT_DR (Hedge&#x02019;s <italic toggle="yes">g</italic> = 0.43, <italic toggle="yes">p</italic> &#x0003c; 0.01), SDMT (Hedge&#x02019;s <italic toggle="yes">g</italic> = 0.41, <italic toggle="yes">p</italic> = 0.01), PASAT_3 sec (Hedge&#x02019;s <italic toggle="yes">g</italic> = 0.51, <italic toggle="yes">p</italic> &#x0003c; 0.01), D-KEFS_CS (Hedge&#x02019;s <italic toggle="yes">g</italic> = 0.44, <italic toggle="yes">p</italic> = 0.03) and D-KEFS_DS (Hedge&#x02019;s <italic toggle="yes">g</italic> = 0.48, <italic toggle="yes">p</italic> = 0.01). There were no significant between-group differences for COWAT or PASAT_2 sec raw scores between participants with previous seizures or not. <xref rid="fig1-13524585251326841" ref-type="fig">Figures 1</xref><xref rid="fig2-13524585251326841" ref-type="fig"/>&#x02013;<xref rid="fig3-13524585251326841" ref-type="fig">3</xref> illustrate comparisons in cognitive raw scores between people with or without prior seizures.</p><table-wrap position="float" id="table2-13524585251326841"><label>Table 2.</label><caption><p>Comparisons in minimal assessment of cognitive function in multiple sclerosis raw scores between people with and without a history of seizures.</p></caption><alternatives><graphic xlink:href="10.1177_13524585251326841-table2" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1">No history of seizures</th><th align="left" colspan="3" rowspan="1">History of seizures</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">t</italic>
</th><th align="left" rowspan="2" colspan="1">Hedges&#x02019; <italic toggle="yes">g</italic></th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">M</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SD</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">M</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">SD</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">COWAT</td><td rowspan="1" colspan="1">756</td><td rowspan="1" colspan="1">36.19</td><td rowspan="1" colspan="1">11.36</td><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">33.79</td><td rowspan="1" colspan="1">13.31</td><td rowspan="1" colspan="1">&#x02212;1.32</td><td rowspan="1" colspan="1">0.21</td></tr><tr><td rowspan="1" colspan="1">JOLO</td><td rowspan="1" colspan="1">748</td><td rowspan="1" colspan="1">23.79</td><td rowspan="1" colspan="1">4.50</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">21.28</td><td rowspan="1" colspan="1">5.94</td><td rowspan="1" colspan="1">&#x02212;3.38<xref rid="table-fn5-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.55</td></tr><tr><td rowspan="1" colspan="1">CVLT_TL</td><td rowspan="1" colspan="1">759</td><td rowspan="1" colspan="1">51.96</td><td rowspan="1" colspan="1">12.82</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">45.98</td><td rowspan="1" colspan="1">12.94</td><td rowspan="1" colspan="1">&#x02212;2.97<xref rid="table-fn5-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.47</td></tr><tr><td rowspan="1" colspan="1">CVLT_DR</td><td rowspan="1" colspan="1">757</td><td rowspan="1" colspan="1">10.98</td><td rowspan="1" colspan="1">4.05</td><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">8.88</td><td rowspan="1" colspan="1">4.56</td><td rowspan="1" colspan="1">&#x02212;3.25<xref rid="table-fn5-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.49</td></tr><tr><td rowspan="1" colspan="1">BVMT_TL</td><td rowspan="1" colspan="1">749</td><td rowspan="1" colspan="1">22.47</td><td rowspan="1" colspan="1">7.54</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">18.90</td><td rowspan="1" colspan="1">7.48</td><td rowspan="1" colspan="1">&#x02212;2.95<xref rid="table-fn5-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.47</td></tr><tr><td rowspan="1" colspan="1">BVMT_DR</td><td rowspan="1" colspan="1">749</td><td rowspan="1" colspan="1">8.46</td><td rowspan="1" colspan="1">2.94</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">7.20</td><td rowspan="1" colspan="1">3.03</td><td rowspan="1" colspan="1">&#x02212;2.67<xref rid="table-fn5-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.43</td></tr><tr><td rowspan="1" colspan="1">SDMT</td><td rowspan="1" colspan="1">749</td><td rowspan="1" colspan="1">48.98</td><td rowspan="1" colspan="1">13.07</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">43.68</td><td rowspan="1" colspan="1">12.35</td><td rowspan="1" colspan="1">&#x02212;2.51<xref rid="table-fn5-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">0.41</td></tr><tr><td rowspan="1" colspan="1">PASAT_3 sec</td><td rowspan="1" colspan="1">723</td><td rowspan="1" colspan="1">39.70</td><td rowspan="1" colspan="1">12.09</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">33.51</td><td rowspan="1" colspan="1">13.79</td><td rowspan="1" colspan="1">&#x02212;3.09<xref rid="table-fn5-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.51</td></tr><tr><td rowspan="1" colspan="1">PASAT_2 sec</td><td rowspan="1" colspan="1">658</td><td rowspan="1" colspan="1">30.78</td><td rowspan="1" colspan="1">9.38</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">28.73</td><td rowspan="1" colspan="1">11.63</td><td rowspan="1" colspan="1">&#x02212;1.21</td><td rowspan="1" colspan="1">0.22</td></tr><tr><td rowspan="1" colspan="1">D-KEFS_CS</td><td rowspan="1" colspan="1">753</td><td rowspan="1" colspan="1">9.41</td><td rowspan="1" colspan="1">2.71</td><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">8.21</td><td rowspan="1" colspan="1">3.35</td><td rowspan="1" colspan="1">&#x02212;2.28<xref rid="table-fn5-13524585251326841" ref-type="table-fn">*</xref>,<sup>
<xref rid="table-fn4-13524585251326841" ref-type="table-fn">a</xref>
</sup></td><td rowspan="1" colspan="1">0.44</td></tr><tr><td rowspan="1" colspan="1">D-KEFS_DS</td><td rowspan="1" colspan="1">753</td><td rowspan="1" colspan="1">35.40</td><td rowspan="1" colspan="1">10.84</td><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">30.12</td><td rowspan="1" colspan="1">12.95</td><td rowspan="1" colspan="1">&#x02212;2.59<xref rid="table-fn5-13524585251326841" ref-type="table-fn">*</xref>,<sup>
<xref rid="table-fn4-13524585251326841" ref-type="table-fn">a</xref>
</sup></td><td rowspan="1" colspan="1">0.48</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn3-13524585251326841"><p><italic toggle="yes">n</italic>: Number of participants; COWAT: Controlled Oral Word Association Test; JOLO: Judgement of Line Orientation; CVLT_TL: California Verbal Learning Test (second edition) total learning; CVLT_DR: California Verbal Learning Test (second edition) delayed recall; BVMT_TL: Brief Visuospatial Memory Test-Revised total learning; BVMT_DR: Brief Visuospatial Memory Test-Revised delayed recall; SDMT: Symbol Digit Modalities Test; PASAT_3 sec: Paced Auditory Serial Addition Test 3 seconds; PASAT_2 sec: Paced Auditory Serial Addition Test 2 seconds; D-KEFS_CS: Delis-Kaplan Executive Function System correct sorts score; D-KEFS_DS: Delis-Kaplan Executive Function System descriptive score.</p></fn><fn id="table-fn4-13524585251326841"><label>a</label><p>Significant Levene&#x02019;s test, and thus, Welch&#x02019;s <italic toggle="yes">t</italic>-test used. Student&#x02019;s <italic toggle="yes">t</italic>-test used in all other comparisons.</p></fn><fn id="table-fn5-13524585251326841"><label>*</label><p><italic toggle="yes">p</italic> &#x0003c; 0.05; **<italic toggle="yes">p</italic> &#x0003c; 0.01.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="fig1-13524585251326841"><label>Figure 1.</label><caption><p>Comparisons between people with and without a seizure history on raw scores of tests of executive function and visuospatial processing. (a) COWAT, (b) JOLO, (c) D-KEFS_CS and (d) D-KEFS_DS.</p><p>COWAT: Controlled Oral Word Association Test; JOLO: Judgement of Line Orientation; D-KEFS_CS: Delis-Kaplan Executive Function System correct sorts score; D-KEFS_DS: Delis-Kaplan Executive Function System descriptive score. Error bars indicate sub-group standard errors. Bracket and associated numbers reflect the sample mean difference and associated 95% confidence interval (95% CI).</p><p>*<italic toggle="yes">p</italic> &#x0003c; 0.05; **<italic toggle="yes">p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="10.1177_13524585251326841-fig1" position="float"/></fig><fig position="float" id="fig2-13524585251326841"><label>Figure 2.</label><caption><p>Comparisons between people with and without a seizure history on raw scores of tests of learning and memory. (a) CVLT_TL, (b) CVLT_DR, (c) BVMT_TL and (d) BVMT_DR.</p><p>CVLT_TL: California Verbal Learning Test (second edition) total learning; CVLT_DR: California Verbal Learning Test (second edition) delayed recall; BVMT_TL: Brief Visuospatial Memory Test-revised total learning; BVMT_DR: Brief Visuospatial Memory Test-revised delayed recall. Error bars indicate sub-group standard errors. Bracket and associated numbers reflect the sample mean difference and associated 95% confidence interval (95% CI).</p><p>*<italic toggle="yes">p</italic> &#x0003c; 0.05; **<italic toggle="yes">p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="10.1177_13524585251326841-fig2" position="float"/></fig><fig position="float" id="fig3-13524585251326841"><label>Figure 3.</label><caption><p>Comparisons between people with and without a seizure history on raw scores of tests of processing speed and working memory. (a) SDMT, (b) PASAT_3 sec and (c). PASAT_2 sec.</p><p>SDMT: Symbol Digit Modalities Test; PASAT_3 sec: Paced Auditory Serial Addition Test 3 seconds; PASAT_2 sec: Paced Auditory Serial Addition Test 2 seconds. Error bars indicate sub-group standard errors. Bracket and associated numbers reflect the sample mean difference and associated 95% confidence interval (95% CI).</p><p>*<italic toggle="yes">p</italic> &#x0003c; 0.05; **<italic toggle="yes">p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="10.1177_13524585251326841-fig3" position="float"/></fig><p>After adjusting for covariates, seizure history was an independent predictor of decreased scores on the JOLO (&#x003b2; = &#x02212;0.09, <italic toggle="yes">p</italic> &#x0003c; 0.01), CVLT_TL (&#x003b2; = &#x02212;0.08, <italic toggle="yes">p</italic> &#x0003c; 0.01), CVLT_DR (&#x003b2; = &#x02212;0.10, <italic toggle="yes">p</italic> &#x0003c; 0.01), BVMT_TL (&#x003b2; = &#x02212;0.08, <italic toggle="yes">p</italic> = 0.01), BVMT_DR (&#x003b2; = &#x02212;0.07, <italic toggle="yes">p</italic> = 0.05), SDMT (&#x003b2; = &#x02212;0.06, <italic toggle="yes">p</italic> = 0.04), PASAT_3 sec (&#x003b2; = &#x02212;0.10, <italic toggle="yes">p</italic> &#x0003c; 0.01) and D-KEFS_DS (&#x003b2; = &#x02212;0.07, <italic toggle="yes">p</italic> = 0.02). Seizure history did not independently predict COWAT, PASAT_2 sec and D-KEFS_CS raw scores. <xref rid="table3-13524585251326841" ref-type="table">Table 3</xref> includes all of the standardized beta coefficients from these regression models.</p><table-wrap position="float" id="table3-13524585251326841"><label>Table 3.</label><caption><p>Standardized beta coefficients from linear regression analyses to predict minimal assessment of cognitive function in multiple sclerosis raw scores from seizure history, adjusted for covariates.</p></caption><alternatives><graphic xlink:href="10.1177_13524585251326841-table3" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="13" rowspan="1">Standardized beta coefficients</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">R</italic>
<sup>2</sup>
</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Sz. Hx.</th><th align="left" rowspan="1" colspan="1">Age</th><th align="left" rowspan="1" colspan="1">Sex</th><th align="left" rowspan="1" colspan="1">WTAR</th><th align="left" rowspan="1" colspan="1">Edu.</th><th align="left" rowspan="1" colspan="1">EDSS</th><th align="left" rowspan="1" colspan="1">Dx. Dur.</th><th align="left" rowspan="1" colspan="1">RMSv PMS</th><th align="left" rowspan="1" colspan="1">HET use</th><th align="left" rowspan="1" colspan="1">HADS-D</th><th align="left" rowspan="1" colspan="1">HADS-A</th><th align="left" rowspan="1" colspan="1">Inter.</th><th align="left" rowspan="1" colspan="1">MFIS</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">COWAT</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">0.42<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">&#x02212;0.18<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">&#x02212;0.10<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">0.27</td></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI LL</td><td rowspan="1" colspan="1">&#x02212;0.08</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">0.35</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">&#x02212;0.27</td><td rowspan="1" colspan="1">&#x02212;0.09</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">&#x02212;0.04</td><td rowspan="1" colspan="1">&#x02212;0.18</td><td rowspan="1" colspan="1">&#x02212;0.02</td><td rowspan="1" colspan="1">&#x02212;0.11</td><td rowspan="1" colspan="1">&#x02212;0.15</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI UL</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.14</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">0.49</td><td rowspan="1" colspan="1">0.10</td><td rowspan="1" colspan="1">&#x02212;0.10</td><td rowspan="1" colspan="1">0.10</td><td rowspan="1" colspan="1">0.10</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">0.13</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">JOLO</td><td rowspan="1" colspan="1">&#x02212;0.09<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.10<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">&#x02212;0.20<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.35<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.04</td><td rowspan="1" colspan="1">&#x02212;0.15<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.02</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">&#x02212;0.07<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">&#x02212;0.09<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">0.21</td></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI LL</td><td rowspan="1" colspan="1">&#x02212;0.15</td><td rowspan="1" colspan="1">&#x02212;0.18</td><td rowspan="1" colspan="1">&#x02212;0.27</td><td rowspan="1" colspan="1">0.29</td><td rowspan="1" colspan="1">&#x02212;0.11</td><td rowspan="1" colspan="1">&#x02212;0.24</td><td rowspan="1" colspan="1">&#x02212;0.10</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">&#x02212;0.08</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">&#x02212;0.13</td><td rowspan="1" colspan="1">&#x02212;0.14</td><td rowspan="1" colspan="1">&#x02212;0.17</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI UL</td><td rowspan="1" colspan="1">&#x02212;0.02</td><td rowspan="1" colspan="1">&#x02212;0.02</td><td rowspan="1" colspan="1">&#x02212;0.13</td><td rowspan="1" colspan="1">0.42</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.14</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">0.12</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">CVLT_TL</td><td rowspan="1" colspan="1">&#x02212;0.08<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.11<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.19<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.21<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.18<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.26<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">0.31</td></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI LL</td><td rowspan="1" colspan="1">&#x02212;0.14</td><td rowspan="1" colspan="1">&#x02212;0.18</td><td rowspan="1" colspan="1">0.12</td><td rowspan="1" colspan="1">0.15</td><td rowspan="1" colspan="1">0.12</td><td rowspan="1" colspan="1">&#x02212;0.34</td><td rowspan="1" colspan="1">&#x02212;0.14</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">&#x02212;0.14</td><td rowspan="1" colspan="1">&#x02212;0.04</td><td rowspan="1" colspan="1">&#x02212;0.11</td><td rowspan="1" colspan="1">&#x02212;0.13</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI UL</td><td rowspan="1" colspan="1">&#x02212;0.02</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">0.25</td><td rowspan="1" colspan="1">0.28</td><td rowspan="1" colspan="1">0.25</td><td rowspan="1" colspan="1">&#x02212;0.18</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.10</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.11</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">CVLT_DR</td><td rowspan="1" colspan="1">&#x02212;0.10<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.09<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">0.16<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.20<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.16<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.23<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.10<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">&#x02212;0.10<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">0.27</td></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI LL</td><td rowspan="1" colspan="1">&#x02212;0.16</td><td rowspan="1" colspan="1">&#x02212;0.16</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">0.14</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">&#x02212;0.31</td><td rowspan="1" colspan="1">&#x02212;0.18</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">&#x02212;0.10</td><td rowspan="1" colspan="1">&#x02212;0.19</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">&#x02212;0.11</td><td rowspan="1" colspan="1">&#x02212;0.08</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI UL</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">0.22</td><td rowspan="1" colspan="1">0.27</td><td rowspan="1" colspan="1">0.22</td><td rowspan="1" colspan="1">&#x02212;0.14</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">0.10</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">0.14</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">BVMT_TL</td><td rowspan="1" colspan="1">&#x02212;0.08<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">&#x02212;0.26<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.28<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">&#x02212;0.19<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">0.26</td></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI LL</td><td rowspan="1" colspan="1">&#x02212;0.14</td><td rowspan="1" colspan="1">&#x02212;0.33</td><td rowspan="1" colspan="1">&#x02212;0.04</td><td rowspan="1" colspan="1">0.21</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">&#x02212;0.28</td><td rowspan="1" colspan="1">&#x02212;0.15</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">&#x02212;0.08</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">&#x02212;0.12</td><td rowspan="1" colspan="1">&#x02212;0.15</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI UL</td><td rowspan="1" colspan="1">&#x02212;0.02</td><td rowspan="1" colspan="1">&#x02212;0.18</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">0.35</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">&#x02212;0.11</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.11</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">0.12</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">BVMT_DR</td><td rowspan="1" colspan="1">&#x02212;0.07<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">&#x02212;0.23<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.26<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">&#x02212;0.19<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">&#x02212;0.08</td><td rowspan="1" colspan="1">0.23</td></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI LL</td><td rowspan="1" colspan="1">&#x02212;0.13</td><td rowspan="1" colspan="1">&#x02212;0.31</td><td rowspan="1" colspan="1">&#x02212;0.04</td><td rowspan="1" colspan="1">0.19</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">&#x02212;0.27</td><td rowspan="1" colspan="1">&#x02212;0.15</td><td rowspan="1" colspan="1">&#x02212;0.02</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">&#x02212;0.04</td><td rowspan="1" colspan="1">&#x02212;0.11</td><td rowspan="1" colspan="1">&#x02212;0.17</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI UL</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">&#x02212;0.14</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">0.33</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">&#x02212;0.10</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.14</td><td rowspan="1" colspan="1">0.08</td><td rowspan="1" colspan="1">0.10</td><td rowspan="1" colspan="1">0.12</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SDMT</td><td rowspan="1" colspan="1">&#x02212;0.06<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">&#x02212;0.18<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.22<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">&#x02212;0.32<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">0.12<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">&#x02212;0.09<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.13<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.33</td></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI LL</td><td rowspan="1" colspan="1">&#x02212;0.12</td><td rowspan="1" colspan="1">&#x02212;0.26</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">0.16</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">&#x02212;0.40</td><td rowspan="1" colspan="1">&#x02212;0.14</td><td rowspan="1" colspan="1">&#x02212;0.04</td><td rowspan="1" colspan="1">&#x02212;0.09</td><td rowspan="1" colspan="1">&#x02212;0.09</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">&#x02212;0.15</td><td rowspan="1" colspan="1">&#x02212;0.21</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI UL</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">&#x02212;0.11</td><td rowspan="1" colspan="1">0.11</td><td rowspan="1" colspan="1">0.29</td><td rowspan="1" colspan="1">0.08</td><td rowspan="1" colspan="1">&#x02212;0.24</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">0.11</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.08</td><td rowspan="1" colspan="1">0.19</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PASAT_3 sec</td><td rowspan="1" colspan="1">&#x02212;0.10<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">&#x02212;0.13<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.31<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.08<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">&#x02212;0.22<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.09<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">&#x02212;0.09</td><td rowspan="1" colspan="1">0.20</td></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI LL</td><td rowspan="1" colspan="1">&#x02212;0.16</td><td rowspan="1" colspan="1">&#x02212;0.11</td><td rowspan="1" colspan="1">&#x02212;0.20</td><td rowspan="1" colspan="1">0.24</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">&#x02212;0.31</td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">&#x02212;0.10</td><td rowspan="1" colspan="1">&#x02212;0.18</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI UL</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">0.39</td><td rowspan="1" colspan="1">0.15</td><td rowspan="1" colspan="1">&#x02212;0.13</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">0.17</td><td rowspan="1" colspan="1">0.08</td><td rowspan="1" colspan="1">0.11</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PASAT_2 sec</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">&#x02212;0.13<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.23<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.11<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.15<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.04</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">&#x02212;0.14<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.15</td></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI LL</td><td rowspan="1" colspan="1">&#x02212;0.10</td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">&#x02212;0.20</td><td rowspan="1" colspan="1">0.15</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">&#x02212;0.25</td><td rowspan="1" colspan="1">&#x02212;0.13</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">&#x02212;0.08</td><td rowspan="1" colspan="1">&#x02212;0.11</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">&#x02212;0.10</td><td rowspan="1" colspan="1">&#x02212;0.24</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI UL</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.11</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">0.31</td><td rowspan="1" colspan="1">0.19</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.08</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">0.12</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">&#x02212;0.04</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">D-KEFS_CS</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">&#x02212;0.16<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.08<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">0.29<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.17<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.24<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">&#x02212;0.02</td><td rowspan="1" colspan="1">&#x02212;0.02</td><td rowspan="1" colspan="1">0.26</td></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI LL</td><td rowspan="1" colspan="1">&#x02212;0.13</td><td rowspan="1" colspan="1">&#x02212;0.24</td><td rowspan="1" colspan="1">&#x02212;0.14</td><td rowspan="1" colspan="1">0.22</td><td rowspan="1" colspan="1">0.10</td><td rowspan="1" colspan="1">&#x02212;0.33</td><td rowspan="1" colspan="1">&#x02212;0.07</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">&#x02212;0.14</td><td rowspan="1" colspan="1">&#x02212;0.08</td><td rowspan="1" colspan="1">&#x02212;0.09</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI UL</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">&#x02212;0.08</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">0.36</td><td rowspan="1" colspan="1">0.24</td><td rowspan="1" colspan="1">&#x02212;0.016</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">0.12</td><td rowspan="1" colspan="1">0.11</td><td rowspan="1" colspan="1">0.16</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">D-KEFS_DS</td><td rowspan="1" colspan="1">&#x02212;0.07<xref rid="table-fn7-13524585251326841" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">&#x02212;0.13<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">0.34<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">0.14<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.24<xref rid="table-fn7-13524585251326841" ref-type="table-fn">**</xref></td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">&#x02212;0.02</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">0.27</td></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI LL</td><td rowspan="1" colspan="1">&#x02212;0.14</td><td rowspan="1" colspan="1">&#x02212;0.21</td><td rowspan="1" colspan="1">&#x02212;0.12</td><td rowspan="1" colspan="1">0.27</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">&#x02212;0.33</td><td rowspan="1" colspan="1">&#x02212;0.09</td><td rowspan="1" colspan="1">&#x02212;0.04</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">&#x02212;0.02</td><td rowspan="1" colspan="1">&#x02212;0.13</td><td rowspan="1" colspan="1">&#x02212;0.09</td><td rowspan="1" colspan="1">&#x02212;0.10</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI UL</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">&#x02212;0.06</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">0.40</td><td rowspan="1" colspan="1">0.21</td><td rowspan="1" colspan="1">&#x02212;0.16</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">0.12</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">0.15</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn6-13524585251326841"><p>Sz. Hx.: seizure history; WTAR: Wechsler Test of Adult Reading; Edu.: years of education; EDSS: Expanded Disability Status Scale; Dx. Dur.: disease duration; RMSvPMS: Relapsing-Remitting Multiple Sclerosis versus Progressive Multiple Sclerosis; HET: high-efficacy therapy; HADS-D: Centred Hospital Anxiety and Depression Scale sub-scales for depression; HADS-A: Centred Hospital Anxiety and Depression Scale sub-scales for anxiety; Inter.: Interaction between depression and anxiety; MFIS: Modified Fatigue Impact Scale; COWAT: Controlled Oral Word Association Test; 95% CI: 95% confidence interval; LL: lower limit; UL: upper limit; JOLO: Judgement of Line Orientation; CVLT_TL: California Verbal Learning Test (second edition) total learning; CVLT_DR: California Verbal Learning Test (second edition) delayed recall; BVMT_TL: Brief Visuospatial Memory Test-Revised total learning; Brief Visuospatial Memory Test-Revised total learning delayed recall; SDMT: Symbol Digit Modalities Test; PASAT_3 sec: Paced Auditory Serial Addition Test 3 seconds; PASAT_2 sec: Paced Auditory Serial Addition Test 3 seconds; D-KEFS_CS: Delis-Kaplan Executive Function System correct sorts score; D-KEFS_DS: Delis-Kaplan Executive Function System descriptive score.</p></fn><fn id="table-fn7-13524585251326841"><label>*</label><p><italic toggle="yes">p</italic> &#x0003c; 0.05; **<italic toggle="yes">p</italic> &#x0003c; 0.01.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="section15-13524585251326841"><title>Discussion</title><p>Findings from a consecutive sample of 803 pwMS revealed that individuals with a self-reported history of seizures were more impaired than those without across multiple cognitive domains. These findings are in keeping with the non-MS literature,<sup><xref rid="bibr18-13524585251326841" ref-type="bibr">18</xref>,<xref rid="bibr19-13524585251326841" ref-type="bibr">19</xref></sup> and while similar results have been reported in a smaller MS literature,<sup><xref rid="bibr20-13524585251326841" ref-type="bibr">20</xref>,<xref rid="bibr21-13524585251326841" ref-type="bibr">21</xref></sup> our study is, to the best of our knowledge, the first to demonstrate that a history of seizures per se is an independent predictor of cognitive dysfunction in pwMS. We examine this finding in detail and discuss its potential implications for future research and clinical care.</p><p>Only two studies have examined the association between seizure history and objectively measured cognition in pwMS.<sup><xref rid="bibr20-13524585251326841" ref-type="bibr">20</xref>,<xref rid="bibr21-13524585251326841" ref-type="bibr">21</xref></sup> In a 3-year case&#x02013;control longitudinal study of 92 people with relapsing-remitting MS, Calabrese and colleagues found that those with epilepsy (case) demonstrated worse cognitive performance and faster cognitive decline compared to people without epilepsy (control).<sup>
<xref rid="bibr20-13524585251326841" ref-type="bibr">20</xref>
</sup> In another study (including only 10 participants who had seizures), Uribe-San-Martin and colleagues found a link between poor seizure control and reduced cognitive performance.<sup>
<xref rid="bibr21-13524585251326841" ref-type="bibr">21</xref>
</sup> However, both of these studies had small samples and did not control for the influence of potential confounding demographic, disease-related or neuropsychiatric variables.<sup><xref rid="bibr20-13524585251326841" ref-type="bibr">20</xref>,<xref rid="bibr21-13524585251326841" ref-type="bibr">21</xref></sup></p><p>There are several potential explanations for this association. Ictal or inter-ictal activity could worsen cognition, aligning with the general population literature,<sup>
<xref rid="bibr18-13524585251326841" ref-type="bibr">18</xref>
</sup> and evidence from a small sample of pwMS showing that adequate seizure control improves cognitive performance.<sup>
<xref rid="bibr21-13524585251326841" ref-type="bibr">21</xref>
</sup> Alternatively, MS-related brain changes may increase the risk of both seizures and cognitive dysfunction. For example, cortical pathology is linked to seizure history and cognitive dysfunction in pwMS.<sup><xref rid="bibr2-13524585251326841" ref-type="bibr">2</xref>,<xref rid="bibr13-13524585251326841" ref-type="bibr">13</xref>,<xref rid="bibr14-13524585251326841" ref-type="bibr">14</xref>,<xref rid="bibr20-13524585251326841" ref-type="bibr">20</xref>,<xref rid="bibr21-13524585251326841" ref-type="bibr">21</xref></sup> In pwMS who have epilepsy, temporal lobe seizures are common<sup><xref rid="bibr13-13524585251326841" ref-type="bibr">13</xref>,<xref rid="bibr14-13524585251326841" ref-type="bibr">14</xref></sup> and associated with severe hippocampal damage.<sup>
<xref rid="bibr13-13524585251326841" ref-type="bibr">13</xref>
</sup> In relapsing-remitting MS, epilepsy was associated with increased cortical lesions, decreased cortical thickness, and a faster decline in grey matter fraction over 3 years compared to people without epilepsy.<sup>
<xref rid="bibr20-13524585251326841" ref-type="bibr">20</xref>
</sup> Furthermore, in pwMS who have seizures, poor seizure control was linked to reduced brain volume and cortical lesions.<sup>
<xref rid="bibr21-13524585251326841" ref-type="bibr">21</xref>
</sup> Together, these early data suggest a connection between seizure history and cortical pathology in pwMS. Longitudinal studies will be needed to clarify the temporal order of the connection between seizures and cognition in pwMS.</p><p>As previously noted, seizures occur in approximately 1%&#x02013;3% of pwMS.<sup><xref rid="bibr10-13524585251326841" ref-type="bibr">10</xref>,<xref rid="bibr11-13524585251326841" ref-type="bibr">11</xref></sup> Despite our sample being skewed towards milder disability, there is a higher prevalence of seizures (5.35%) in our sample relative to the published literature. This, therefore, suggests another potential source of bias &#x02013; pwMS are referred because of neurologists&#x02019; concerns about cognition. A sample biased towards cognitive impairment would by reverse association, be expected to have a higher percentage of people with seizures, as seen in our sample. This emphasizes the importance of routine questions about seizure history in MS neuropsychiatric evaluations, particularly in light of the potential for several psychotropic medications to alter the seizure threshold.</p><p>There are a few limitations of this study to consider. Given the low prevalence of seizure disorders in pwMS and that only a small proportion of the cohort had seizures, it is possible that there was a lack of power to detect differences. Nonetheless, this is one of the largest cohorts where this question has been evaluated and there were no significant differences in demographic, disease-related or neuropsychiatric data between those with or without seizures. As such, further study is required. Our sample is biased towards people with relapsing illness. Although this is typical of a tertiary neuropsychiatry clinic,<sup>
<xref rid="bibr7-13524585251326841" ref-type="bibr">7</xref>
</sup> seizures occur more commonly in people with progressive illness and future studies should bolster enrolment of these individuals.<sup>
<xref rid="bibr12-13524585251326841" ref-type="bibr">12</xref>
</sup> Notably, we did not find an association between seizure history and progressive disease in the preliminary Chi-square test possibly due to a small sample size. Furthermore, accounting for disease subtype did not affect the relationship between seizure history and cognition. We also lack neuroimaging, electroencephalographic or recent disease activity data, or data on socioeconomic variables or medical comorbidities. These data could help clarify whether neuro-anatomical or ictal abnormalities, ongoing disease activity or other variables account for the link between seizure history and cognition.</p><p>In addition, this study relied on self-report of seizure history. In this context, we lack data about seizure semiology, classification or timeline (e.g. age at seizure occurrence, number of seizures, duration of seizures). Yet, all participants in this study were previously assessed and referred by neurologists, potentially enhancing the accuracy of self-reported seizure histories. Nevertheless, it remains unknown whether seizures were active at the time of neuropsychological testing or whether participants were taking specific anti-epileptic medications such as phenytoin or phenobarbital, which some studies,<sup>
<xref rid="bibr35-13524585251326841" ref-type="bibr">35</xref>
</sup> but not all,<sup>
<xref rid="bibr18-13524585251326841" ref-type="bibr">18</xref>
</sup> suggest are linked to increased risk of cognitive side effects. Future studies could build upon this work by verifying seizure histories and gathering comprehensive seizure-related data to clarify whether these factors influence the relationship between seizure history and cognition.</p><p>In conclusion, in a large consecutive clinical sample, our data show that a seizure history is associated with cognitive dysfunction in pwMS, independent of demographic data, disease-related variables or neuropsychiatric symptoms. Clinicians could gather a history of seizures to identify those at elevated risk of impaired cognition for comprehensive neuropsychological assessments. While this study cannot disentangle the influences of seizure activity, neuro-anatomical factors and anti-epileptic medications in contributing to this link, it sets up the foundation for the studies that can. Identifying modifiable contributors remains important to reducing cognitive dysfunction in MS. Seizures may be one such factor. At this stage, it is unclear whether improving seizure control would enhance cognition in pwMS; however, our study opens a potential avenue for future exploration.</p></sec><sec sec-type="supplementary-material" id="section16-13524585251326841" specific-use="figshare"><title>Supplemental Material</title><supplementary-material id="suppl1-13524585251326841" position="float" content-type="local-data"><caption><title>sj-docx-1-msj-10.1177_13524585251326841 &#x02013; Supplemental material for Seizure history and cognitive dysfunction in people with multiple sclerosis</title></caption><media xlink:href="sj-docx-1-msj-10.1177_13524585251326841.docx"/><p>Supplemental material, sj-docx-1-msj-10.1177_13524585251326841 for Seizure history and cognitive dysfunction in people with multiple sclerosis by David E Freedman, Jiwon Oh, Cecilia Meza and Anthony Feinstein in Multiple Sclerosis Journal</p></supplementary-material></sec></body><back><fn-group><fn fn-type="other"><p><bold>Data Availability:</bold> The dataset is available from the corresponding author upon reasonable request.</p></fn><fn fn-type="COI-statement"><p>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Oh has received grants from Biogen-Idec, Roche and EMD-Serono; consulting fees from Biogen-Idec, EMD-Serono, BMS, Novartis, Eli-Lilly, Sanofi and Roche; payment or honoraria from EMD-Serono, Biogen-Idec, Novartis, Roche and Sanofi; participation on a Data Safety Monitoring or Advisory Board for Biogen-Idec, EMD-Serono, Roche, Novartis and Sanofi; and leadership or fiduciary role as Chair of Medical Advisory Committee for MS Society of Canada during the conduct of this study. Dr. Feinstein has received grants from MS Society of Canada, CIHR and Bristol Myers Squibb; royalties from Johns Hopkins University Press and Cambridge University Press; and honoraria from Novartis during the conduct of this study. All other authors have no relevant financial or non-financial interests to disclose.</p></fn><fn fn-type="other"><p><bold>Ethical Considerations and Consent to Participate:</bold> The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Sunnybrook Health Sciences Centre (no. 5263) on 30 December 2021, with the need for written informed consent waived.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was completed as part of a Multiple Sclerosis Neuropsychiatry Fellowship supported by the Sunnybrook Foundation.</p></fn><fn fn-type="other"><p><bold>ORCID iDs:</bold> David E Freedman <inline-graphic xlink:href="10.1177_13524585251326841-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0003-4340-3232" ext-link-type="uri">https://orcid.org/0000-0003-4340-3232</ext-link></p><p>Jiwon Oh <inline-graphic xlink:href="10.1177_13524585251326841-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0001-5519-6088" ext-link-type="uri">https://orcid.org/0000-0001-5519-6088</ext-link></p><p>Anthony Feinstein <inline-graphic xlink:href="10.1177_13524585251326841-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0002-0132-0909" ext-link-type="uri">https://orcid.org/0000-0002-0132-0909</ext-link></p></fn><fn fn-type="supplementary-material"><p><bold>Supplemental Material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-13524585251326841"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ruano</surname><given-names>L</given-names></name>
<name><surname>Portaccio</surname><given-names>E</given-names></name>
<name><surname>Goretti</surname><given-names>B</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes</article-title>. <source>Mult Scler</source>
<year>2017</year>; <volume>23</volume>(<issue>9</issue>): <fpage>1258</fpage>&#x02013;<lpage>1267</lpage>.<pub-id pub-id-type="pmid">27738090</pub-id>
</mixed-citation></ref><ref id="bibr2-13524585251326841"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Benedict</surname><given-names>RHB</given-names></name>
<name><surname>Amato</surname><given-names>MP</given-names></name>
<name><surname>DeLuca</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Cognitive impairment in multiple sclerosis: Clinical management, MRI, and therapeutic avenues</article-title>. <source>Lancet Neurol</source>
<year>2020</year>; <volume>19</volume>(<issue>10</issue>): <fpage>860</fpage>&#x02013;<lpage>871</lpage>.<pub-id pub-id-type="pmid">32949546</pub-id>
</mixed-citation></ref><ref id="bibr3-13524585251326841"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bergmann</surname><given-names>C</given-names></name>
<name><surname>Becker</surname><given-names>S</given-names></name>
<name><surname>Watts</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Multiple sclerosis and quality of life: The role of cognitive impairment on quality of life in people with multiple sclerosis</article-title>. <source>Mult Scler Relat</source>
<year>2023</year>; <volume>79</volume>: <fpage>104966</fpage>.</mixed-citation></ref><ref id="bibr4-13524585251326841"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Clemens</surname><given-names>L</given-names></name>
<name><surname>Langdon</surname><given-names>D</given-names></name>
</person-group>. <article-title>How does cognition relate to employment in multiple sclerosis? A systematic review</article-title>. <source>Mult Scler Relat Disord</source>
<year>2018</year>; <volume>26</volume>: <fpage>183</fpage>&#x02013;<lpage>191</lpage>.<pub-id pub-id-type="pmid">30268039</pub-id>
</mixed-citation></ref><ref id="bibr5-13524585251326841"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Donaldson</surname><given-names>E</given-names></name>
<name><surname>Patel</surname><given-names>VP</given-names></name>
<name><surname>Shammi</surname><given-names>P</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Why sex matters: A cognitive study of people with multiple sclerosis</article-title>. <source>Cogn Behav Neurol</source>
<year>2019</year>; <volume>32</volume>(<issue>1</issue>): <fpage>39</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">30896576</pub-id>
</mixed-citation></ref><ref id="bibr6-13524585251326841"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Freedman</surname><given-names>DE</given-names></name>
<name><surname>Oh</surname><given-names>J</given-names></name>
<name><surname>Feinstein</surname><given-names>A</given-names></name>
</person-group>. <article-title>Neuropsychiatric status of patients with multiple sclerosis across disease duration intervals</article-title>. <source>J Neuropsychiatry Clin Neurosci</source>
<year>2023</year>; <volume>35</volume>(<issue>3</issue>): <fpage>250</fpage>&#x02013;<lpage>255</lpage>.<pub-id pub-id-type="pmid">36785945</pub-id>
</mixed-citation></ref><ref id="bibr7-13524585251326841"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Freedman</surname><given-names>DE</given-names></name>
<name><surname>Oh</surname><given-names>J</given-names></name>
<name><surname>Kiss</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The influence of depression and anxiety on cognition in people with multiple sclerosis: A cross-sectional analysis</article-title>. <source>J Neurol</source>
<year>2024</year>; <volume>271</volume>(<issue>8</issue>): <fpage>4885</fpage>&#x02013;<lpage>4896</lpage>.<pub-id pub-id-type="pmid">38730098</pub-id>
</mixed-citation></ref><ref id="bibr8-13524585251326841"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bisecco</surname><given-names>A</given-names></name>
<name><surname>Capuano</surname><given-names>R</given-names></name>
<name><surname>Caiazzo</surname><given-names>G</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis</article-title>. <source>Mult Scler</source>
<year>2021</year>; <volume>27</volume>(<issue>1</issue>): <fpage>134</fpage>&#x02013;<lpage>138</lpage>.<pub-id pub-id-type="pmid">31793399</pub-id>
</mixed-citation></ref><ref id="bibr9-13524585251326841"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>De Meo</surname><given-names>E</given-names></name>
<name><surname>Portaccio</surname><given-names>E</given-names></name>
<name><surname>Giorgio</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Identifying the distinct cognitive phenotypes in multiple sclerosis</article-title>. <source>JAMA Neurol</source>
<year>2021</year>; <volume>78</volume>(<issue>4</issue>): <fpage>414</fpage>&#x02013;<lpage>425</lpage>.<pub-id pub-id-type="pmid">33393981</pub-id>
</mixed-citation></ref><ref id="bibr10-13524585251326841"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kuntz</surname><given-names>S</given-names></name>
<name><surname>Wu</surname><given-names>AS</given-names></name>
<name><surname>Matheson</surname><given-names>E</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Association between multiple sclerosis and epilepsy: A systematic review and meta-analysis</article-title>. <source>Mult Scler Relat Disord</source>
<year>2023</year>; <volume>69</volume>: <fpage>104421</fpage>.<pub-id pub-id-type="pmid">36434909</pub-id>
</mixed-citation></ref><ref id="bibr11-13524585251326841"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mirmosayyeb</surname><given-names>O</given-names></name>
<name><surname>Shaygannejad</surname><given-names>V</given-names></name>
<name><surname>Nehzat</surname><given-names>N</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Prevalence of seizure/epilepsy in patients with multiple sclerosis: A systematic review and meta-analysis</article-title>. <source>Int J Prev Med</source>
<year>2021</year>; <volume>12</volume>: <fpage>14</fpage>.<pub-id pub-id-type="pmid">34084311</pub-id>
</mixed-citation></ref><ref id="bibr12-13524585251326841"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pozzilli</surname><given-names>V</given-names></name>
<name><surname>Haggiag</surname><given-names>S</given-names></name>
<name><surname>Di Filippo</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Incidence and determinants of seizures in multiple sclerosis: A meta-analysis of randomised clinical trials</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2024</year>; <volume>95</volume>(<issue>7</issue>): <fpage>612</fpage>&#x02013;<lpage>619</lpage>.<pub-id pub-id-type="pmid">38383156</pub-id>
</mixed-citation></ref><ref id="bibr13-13524585251326841"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Calabrese</surname><given-names>M</given-names></name>
<name><surname>Castellaro</surname><given-names>M</given-names></name>
<name><surname>Bertoldo</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Epilepsy in multiple sclerosis: The role of temporal lobe damage</article-title>. <source>Mult Scler</source>
<year>2017</year>; <volume>23</volume>(<issue>3</issue>): <fpage>473</fpage>&#x02013;<lpage>482</lpage>.<pub-id pub-id-type="pmid">27260699</pub-id>
</mixed-citation></ref><ref id="bibr14-13524585251326841"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nurre</surname><given-names>ER</given-names></name>
<name><surname>Shah</surname><given-names>A</given-names></name>
<name><surname>Hansen</surname><given-names>CJ</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Multiple sclerosis and seizures: A retrospective observational study in a multiple sclerosis autoimmunity center of excellence</article-title>. <source>Seizure</source>
<year>2024</year>; <volume>115</volume>: <fpage>44</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">38183827</pub-id>
</mixed-citation></ref><ref id="bibr15-13524585251326841"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chaudhary</surname><given-names>R</given-names></name>
<name><surname>Albrecht</surname><given-names>S</given-names></name>
<name><surname>Datunashvili</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Modulation of pacemaker channel function in a model of thalamocortical hyperexcitability by demyelination and cytokines</article-title>. <source>Cereb Cortex</source>
<year>2022</year>; <volume>32</volume>(<issue>20</issue>): <fpage>4397</fpage>&#x02013;<lpage>4421</lpage>.<pub-id pub-id-type="pmid">35076711</pub-id>
</mixed-citation></ref><ref id="bibr16-13524585251326841"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Grothe</surname><given-names>M</given-names></name>
<name><surname>Ellenberger</surname><given-names>D</given-names></name>
<name><surname>von Podewils</surname><given-names>F</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Epilepsy as a predictor of disease progression in multiple sclerosis</article-title>. <source>Mult Scler</source>
<year>2022</year>; <volume>28</volume>(<issue>6</issue>): <fpage>942</fpage>&#x02013;<lpage>949</lpage>.<pub-id pub-id-type="pmid">34595974</pub-id>
</mixed-citation></ref><ref id="bibr17-13524585251326841"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chou</surname><given-names>IJ</given-names></name>
<name><surname>Kuo</surname><given-names>CF</given-names></name>
<name><surname>Tanasescu</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Epilepsy and associated mortality in patients with multiple sclerosis</article-title>. <source>Eur J Neurol</source>
<year>2019</year>; <volume>26</volume>(<issue>2</issue>): 342&#x02013;3e23.</mixed-citation></ref><ref id="bibr18-13524585251326841"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Foster</surname><given-names>E</given-names></name>
<name><surname>Malpas</surname><given-names>CB</given-names></name>
<name><surname>Ye</surname><given-names>K</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Antiepileptic drugs are not independently associated with cognitive dysfunction</article-title>. <source>Neurology</source>
<year>2020</year>; <volume>94</volume>(<issue>10</issue>): e1051&#x02013;e1061.</mixed-citation></ref><ref id="bibr19-13524585251326841"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Helmstaedter</surname><given-names>C</given-names></name>
<name><surname>Witt</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Epilepsy and cognition: A bidirectional relationship?</article-title>
<source>Seizure</source>
<year>2017</year>; <volume>49</volume>: <fpage>83</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">28284559</pub-id>
</mixed-citation></ref><ref id="bibr20-13524585251326841"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Calabrese</surname><given-names>M</given-names></name>
<name><surname>Grossi</surname><given-names>P</given-names></name>
<name><surname>Favaretto</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Cortical pathology in multiple sclerosis patients with epilepsy: A 3 year longitudinal study</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2012</year>; <volume>83</volume>(<issue>1</issue>): <fpage>49</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">21890577</pub-id>
</mixed-citation></ref><ref id="bibr21-13524585251326841"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Uribe-San-Mart&#x000ed;n</surname><given-names>R</given-names></name>
<name><surname>Ciampi-D&#x000ed;az</surname><given-names>E</given-names></name>
<name><surname>Suarez-Hern&#x000e1;ndez</surname><given-names>F</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Prevalence of epilepsy in a cohort of patients with multiple sclerosis</article-title>. <source>Seizure</source>
<year>2014</year>; <volume>23</volume>(<issue>1</issue>): <fpage>81</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">24099836</pub-id>
</mixed-citation></ref><ref id="bibr22-13524585251326841"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Reingold</surname><given-names>SC</given-names></name>
<name><surname>Banwell</surname><given-names>B</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria</article-title>. <source>Ann Neurol</source>
<year>2011</year>; <volume>69</volume>(<issue>2</issue>): <fpage>292</fpage>&#x02013;<lpage>302</lpage>.<pub-id pub-id-type="pmid">21387374</pub-id>
</mixed-citation></ref><ref id="bibr23-13524585251326841"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>AJ</given-names></name>
<name><surname>Banwell</surname><given-names>BL</given-names></name>
<name><surname>Barkhof</surname><given-names>F</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria</article-title>. <source>Lancet Neurol</source>
<year>2018</year>; <volume>17</volume>(<issue>2</issue>): <fpage>162</fpage>&#x02013;<lpage>173</lpage>.<pub-id pub-id-type="pmid">29275977</pub-id>
</mixed-citation></ref><ref id="bibr24-13524585251326841"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Von Elm</surname><given-names>E</given-names></name>
<name><surname>Altman</surname><given-names>DG</given-names></name>
<name><surname>Egger</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies</article-title>. <source>Lancet</source>
<year>2007</year>; <volume>370</volume>(<issue>9596</issue>): <fpage>1453</fpage>&#x02013;<lpage>1457</lpage>.<pub-id pub-id-type="pmid">18064739</pub-id>
</mixed-citation></ref><ref id="bibr25-13524585251326841"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kurtzke</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS)</article-title>. <source>Neurology</source>
<year>1983</year>; <volume>33</volume>(<issue>11</issue>): <fpage>1444</fpage>&#x02013;<lpage>1452</lpage>.<pub-id pub-id-type="pmid">6685237</pub-id>
</mixed-citation></ref><ref id="bibr26-13524585251326841"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Benedict</surname><given-names>RH</given-names></name>
<name><surname>Fischer</surname><given-names>JS</given-names></name>
<name><surname>Archibald</surname><given-names>CJ</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Minimal neuropsychological assessment of MS patients: A consensus approach</article-title>. <source>Clin Neuropsychol</source>
<year>2002</year>; <volume>16</volume>(<issue>3</issue>): <fpage>381</fpage>&#x02013;<lpage>397</lpage>.<pub-id pub-id-type="pmid">12607150</pub-id>
</mixed-citation></ref><ref id="bibr27-13524585251326841"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Benedict</surname><given-names>RH</given-names></name>
<name><surname>Cookfair</surname><given-names>D</given-names></name>
<name><surname>Gavett</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)</article-title>. <source>J Int Neuropsychol Soc</source>
<year>2006</year>; <volume>12</volume>(<issue>4</issue>): <fpage>549</fpage>&#x02013;<lpage>558</lpage>.<pub-id pub-id-type="pmid">16981607</pub-id>
</mixed-citation></ref><ref id="bibr28-13524585251326841"><label>28</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Wechsler</surname><given-names>D</given-names></name>
</person-group>. <source>Wechsler Test of Adult Reading: WTAR</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>Psychological Corporation</publisher-name>; <year>2001</year>.</mixed-citation></ref><ref id="bibr29-13524585251326841"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zigmond</surname><given-names>AS</given-names></name>
<name><surname>Snaith</surname><given-names>RP</given-names></name>
</person-group>. <article-title>The Hospital Anxiety and Depression Scale</article-title>. <source>Acta Psychiatr Scand</source>
<year>1983</year>; <volume>67</volume>(<issue>6</issue>): <fpage>361</fpage>&#x02013;<lpage>370</lpage>.<pub-id pub-id-type="pmid">6880820</pub-id>
</mixed-citation></ref><ref id="bibr30-13524585251326841"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Honarmand</surname><given-names>K</given-names></name>
<name><surname>Feinstein</surname><given-names>A</given-names></name>
</person-group>. <article-title>Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients</article-title>. <source>Mult Scler</source>
<year>2009</year>; <volume>15</volume>(<issue>12</issue>): <fpage>1518</fpage>&#x02013;<lpage>1524</lpage>.<pub-id pub-id-type="pmid">19965520</pub-id>
</mixed-citation></ref><ref id="bibr31-13524585251326841"><label>31</label><mixed-citation publication-type="book">
<collab>Multiple Sclerosis Council for Clinical Practice Guidelines</collab>. <source>Fatigue and multiple sclerosis &#x02013; Evidence-based management strategies for fatigue in multiple sclerosis: Clinical practice guidelines</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>The Council</publisher-name>; <year>1998</year>.</mixed-citation></ref><ref id="bibr32-13524585251326841"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Learmonth</surname><given-names>YC</given-names></name>
<name><surname>Dlugonski</surname><given-names>D</given-names></name>
<name><surname>Pilutti</surname><given-names>LA</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Psychometric properties of the Fatigue Severity Scale and the Modified Fatigue Impact Scale</article-title>. <source>J Neurol Sci</source>
<year>2013</year>; <volume>331</volume>(<issue>1&#x02013;2</issue>): <fpage>102</fpage>&#x02013;<lpage>107</lpage>.<pub-id pub-id-type="pmid">23791482</pub-id>
</mixed-citation></ref><ref id="bibr33-13524585251326841"><label>33</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>J</given-names></name>
</person-group>. <part-title>Chapter 9: Multiple regression and correlation analysis</part-title>. In: <person-group person-group-type="editor">
<name><surname>Cohen</surname><given-names>J</given-names></name>
</person-group> (ed.) <source>Statistical power analysis for the behavioral sciences</source>. <edition>2nd ed.</edition>
<publisher-loc>Mahwah, NJ</publisher-loc>: <publisher-name>Lawrence Erlbaum Associates</publisher-name>, <year>1988</year>, pp. <fpage>407</fpage>&#x02013;<lpage>465</lpage>.</mixed-citation></ref><ref id="bibr34-13524585251326841"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Champely</surname><given-names>S</given-names></name>
</person-group>. <article-title>pwr: Basic functions for power analysis (R package version 1.3-0)</article-title>. <year>2020</year>.</mixed-citation></ref><ref id="bibr35-13524585251326841"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Eddy</surname><given-names>CM</given-names></name>
<name><surname>Rickards</surname><given-names>HE</given-names></name>
<name><surname>Cavanna</surname><given-names>AE</given-names></name>
</person-group>. <article-title>The cognitive impact of antiepileptic drugs</article-title>. <source>Ther Adv Neurol Disord</source>
<year>2011</year>; <volume>4</volume>(<issue>6</issue>): <fpage>385</fpage>&#x02013;<lpage>407</lpage>.<pub-id pub-id-type="pmid">22164192</pub-id>
</mixed-citation></ref></ref-list></back></article>